Sign inJoin waitlistJoin the waitlist

Kiran Turaga

Division Chief, Surgical Oncology, Surgery · Yale-New Haven Hospital

Credentials: · · · · · · ·

History

Surgical Oncology Division · Yale-New Haven Hospital
Present
Clinical Trials Office · Yale-New Haven Hospital
Present
Surgical Oncology Division · Yale School of Medicine
Present

Surgery
2001–2008
The Johns Hopkins University
ALL INDIA INST OF MED SCI, ANSARI NAGAR, NEW DELHI, DELHI
1997–2001

Research

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
Cancer Discovery · 2018 · 257 citations
Primary and metastatic peritoneal surface malignancies
Review · Nature Reviews Disease Primers · 2021 · 253 citations
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer
Annals of Surgical Oncology · 2010 · 206 citations

Clark Gamblin
57 papers
OE
Oliver Eng
50 papers · 15 as a fellow
Ankit Dhiman
33 papers · 32 as a resident
Fabian Johnston
32 papers · 6 as a fellow
Ardaman Shergill
31 papers
Varun Bansal
29 papers · 29 as a resident
Blase Polite
26 papers
HW
Hunter Witmer
24 papers · 24 as a resident
Kathleen Christians
20 papers · 1 as a fellow
Susan Tsai
20 papers
John Miura
19 papers
DS
David Su
18 papers · 18 as a resident

Clinical trials

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Principal investigator · Recruiting · Phase 2
Yale University
2026–2028
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
Principal investigator · Recruiting
Yale University
2026–2027
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
Principal investigator · Withdrawn · Phase 2
University of Chicago
2022–2027
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Principal investigator · Completed · Phase 2
University of Chicago
2021–2023